# MicroMed Technology

Startup profile on Capital Atlas: https://capitalatlas.ai/startups/micromed-technology

- Industry: Medical Devices & Equipment
- Headquarters: Houston, US
- Website: www.micromedtech.com
- Total disclosed funding: $23M
- Latest round: Series D (Oct 2, 2002)
- Investors on record: 6

## About

MicroMed Technology specializes in innovative medical technology solutions that enhance patient care outcomes across various healthcare settings, including critical care and rehabilitation facilities.MicroMed Technology, founded in 1995 and headquartered in Houston, US, focuses on developing medical devices that improve patient outcomes. The company received its latest funding of USD 23.000 mn in Series D on October 2, 2002, from a group of investors including Mitsui & Co. Venture Partners and returning investors such as Essex Woodlands and Oxford BioScience Partners. The leadership includes CEOs Ettore Vitali and Rick Dodson.MicroMed Technology primarily offers advanced medical technology solutions that enhance patient outcomes. Their product line includes diagnostic devices and therapeutic systems utilizing innovative microtechnology, addressing medical challenges in critical care and rehabilitation settings. Their clientele spans hospitals and clinics across North America, Europe, and Asia, ensuring broad accessibility to their technologies.MicroMed Technology generates revenue through direct sales of its medical devices and partnerships with healthcare institutions. The company engages in B2B transactions, supplying hospitals and clinics with essential medical products. Revenue is structured around the sale of devices and potential service agreements, customized to meet client needs.MicroMed Technology plans to leverage the recent funding from their Series D round to design and launch upcoming innovative medical products in the next two years. The company is targeting expansion into European and Asian markets by 2025. The funding will support these initiatives, ensuring the company's technology continues to improve patient care and remains accessible to healthcare providers.

## Funding rounds

- Series D, Oct 2, 2002, $23M — Charterhouse Strategic Partners, Essex Woodlands, Oxford Bioscience Partners, Mitsui Global Investment, SV Health Investors, C.E. Unterberg

## Investors

- Charterhouse Strategic Partners (https://capitalatlas.ai/funds/charterhouse-strategic-partners) — Series D
- Essex Woodlands (https://capitalatlas.ai/funds/essex-woodlands) — Series D
- Oxford Bioscience Partners (https://capitalatlas.ai/funds/oxford-bioscience-partners) — Series D
- Mitsui Global Investment (https://capitalatlas.ai/funds/mitsui-global-investment) — Series D
- SV Health Investors (https://capitalatlas.ai/funds/sv-health-investors) — Series D
- C.E. Unterberg — Series D